A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

  • STATUS
    Recruiting
  • End date
    Dec 30, 2030
  • participants needed
    40
  • sponsor
    National Cancer Institute (NCI)
Updated on 27 October 2022
cancer
blood tests
fluorouracil
blood test
dexamethasone
metastasis
oxaliplatin
chemotherapy drug
neutrophil count
liver metastasis
irinotecan
metastatic colorectal cancer
cetuximab
floxuridine
solid tumors
chemotherapy drugs
systemic chemotherapy
solid tumour
hepatic arterial infusion
solid neoplasm

Summary

Background

Many people with colorectal cancer get liver metastases. Standard treatment for this is a combination of chemotherapy drugs. Directing the chemotherapy to the liver may be effective. A device that does this a pump that delivers drugs over 2 weeks at constant rate into the hepatic artery. The person s body temperature causes the drug to flow from the pump. Researchers want to see if this helps people with colorectal metastases to the liver.

Objective

To study the effectiveness of a hepatic artery infusion pump at treating colorectal metastases to the liver.

Eligibility

Adults at least 18 years old with colorectal metastases to the liver

Design

Participants will be screened with:

Medical history

Physical exam

Heart, blood, and urine tests

Scans

Participants will stay in the hospital a few days. A small plastic tube (catheter) will be inserted in an artery into the liver. The catheter will be attached to the pump. That will lie under the skin on the abdomen. It will be small and participants will be able to feel it.

Participants will get treatment in 28-day cycles.

Every Day 1, they will have physical exam, symptom review, and blood tests.

Every 2 weeks, they will come to the clinic to get chemotherapy by a catheter or port.

Every 12 weeks, they will have a scan.

Tissue samples may be taken during the study.

When they finish the drug, participants may have the pump removed. They will repeat the Day 1 tests. They will be called every 6 months to see how they are doing.

Sponsoring Institute: National Cancer Institute

Description

Background
  • Nearly 60% of patients with colorectal cancers will develop liver metastases over the course of their disease.
  • Of patients with metastatic colorectal cancer, the liver will be the sole site of recurrence or the survival-limiting site of disease for 20%.
  • Liver directed therapy, which has taken many forms over the last several decades, is a potential means to prolong survival for properly selected patients and delay progression at that site.
  • Hepatic artery infusion of floxuridine (FUDR) via an implantable hepatic artery infusion pump (HAIP) induces objective clinical response rates of nearly 50% in heavily pretreated patients with metastatic colorectal cancer to the liver.
  • The identification of patients likely to respond to HAIP and those likely to suffer pumprelated adverse events is currently unknown, and has limited the wide-spread adoption of this otherwise well tolerated intervention.
    Objective

-To assess the safety of hepatic artery infusion therapy using the Medtronic pump with the

Codman catheter.

  • To determine the response rate in patients with unresectable metastatic colorectal cancer treated with HAIP chemotherapy as measured by RECIST.
    Eligibility
  • Histologically or cytologically confirmed colorectal adenocarcinoma metastatic to the liver.
  • Patients with liver metastases not amenable to resection to No Evidence of Disease (NED) in one stage.
  • Patients must have received systemic chemotherapy.
  • Age greater than or equal to 18 years.
    Design
  • Single arm, phase II study of HAIP chemotherapy.

Details
Condition Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Carcinoma
Treatment Panitumumab, Cetuximab, Irinotecan, Oxaliplatin, Leucovorin, 5-fluorouracil, floxuridine, 5FU, Medtronic pump and Codman catheter, OneRNA, FUDR-Dex, HAIP, Medtronic SynchroMed II Pump with Codman 3000 Constant Flow Pump Catheter, HAIP installation, Codman 3000 constant flow pump catheter, Medtronic SynchroMed II Pump
Clinical Study IdentifierNCT03366155
SponsorNational Cancer Institute (NCI)
Last Modified on27 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must have histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma, confirmed by the Laboratory of Pathology, NCI
Patients must have measurable liver metastatic disease
Patients must have progressed on, been intolerant of or have residual disease after oxaliplatin- or irinotecan-containing, fluorouracil-based, chemotherapeutic regimen
Age greater than or equal to 18 years
ECOG performance status less than or equal to 1
Patients must have adequate organ and marrow function as defined below
leukocytes > 3,000/mcL
absolute neutrophil count > 1,500/mcL
platelets > 90,000/mcL
total bilirubin < 1.5 X institutional upper limit of normal
AST(SGOT)/ALT(SGPT) < 2.5 X institutional upper limit of normal
creatinine within normal institutional limits OR eGFR within normal as predicted by the CKD-EPI equation > 60 mL/min/1.73 m2
The hepatic artery infusion pump chemotherapy has potential teratogenic and/or
Arterial anatomy on CT angiogram amenable to placement of the HAIP
abortifacient effects. For this reason, women of child-bearing potential and
Ability of subject to understand and the willingness to sign a written informed consent document
men must agree to use adequate contraception (hormonal or barrier method of
HIV-positive patients may be considered for this study only after consultation with an HIV trained physician
birth control; abstinence) prior to study entry, for the duration of study
Patients must agree to co-enroll on the Surgical Oncology Program s tissue collection protocol 13C0176, 'Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors'
participation and for 3 months after completion of study treatment. Should a
woman become pregnant or suspect she is pregnant while she or her partner is
participating in this study, she should inform her treating physician
immediately

Exclusion Criteria

Patients with liver metastases amenable to resection to No Evidence of Disease (NED) in one stage
Patients who are receiving any other investigational agents
Patients with incontrovertible radiographic evidence of disease outside of the colon/rectum (primary) and liver given unlikelihood of benefit from liver-directed therapy
Note: The exception to this exclusion is patients with fewer than five lung lesions greater
than 1 cm that have not increased in size by more than 10% over a 4-month period of time
MSI-high patients who need to be treated with a check-point inhibitors
and are amenable to resection should subsequent problematic growth occur. Lesions less than
cm are indeterminant as far as etiology is concerned and will be ignored. Patients with
liver metastases and oligometastatic lung lesions (we define oligometastatic as less than 5
Prior radiation to liver
amen ble to thoracoscopic removal) are still likely to benefit from liver directed therapy
Patients who have undergone extra-hepatic metastasectomy and have a documented
disease-free interval less than or equal to 4 months
Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements. This also includes any condition, including the presence of
laboratory abnormalities, which in the opinion of the Principal Investigator places
the subject at unacceptable risk if they were to participate in the study or confounds
the ability to interpret data from the study
Active concurrent malignancies within the last five years other than colorectal
primary except basal cell skin carcinoma and thyroid carcinoma
Pregnant women are excluded from this study because of the potential for teratogenic
or abortifacient effects of the HAIP chemotherapy. Because there is an unknown but
potential risk for adverse events in nursing infants secondary to treatment of the
mother with HAIP, breastfeeding should be discontinued if the mother is treated. These
potential risks may also apply to other agents used in this study
Patients with active Hepatitis B or C infection because of the potential for increased
liver toxicity given the damaging effects of the virus
History of allergic reactions attributed to compounds of similar chemical composition
to FUDR or heparin
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note